Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

被引：0
|
作者：
Sizheng Zhao
Laura Chadwick
Eduardo Mysler
Robert J. Moots
机构：
[1] University of Liverpool,Department of Musculoskeletal Biology I, Clinical Sciences Centre, Institute of Ageing and Chronic Disease
[2] Aintree University Hospital,undefined
[3] Organización Medica de Investigación,undefined
来源：
Current Rheumatology Reports | 2018年 / 20卷
关键词：
Adalimumab; Biosimilar; Rheumatoid arthritis; Amgevita; Cyltezo; Imraldi;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Real-World Utilization of Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis in Europe
    Jin, Ran
    Hughes, Megan
    Goddard, Emily
    Piercy, James
    Courmier, Delphine
    Meadows, Rachael
    Radziszewski, Waldemar
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2729 - 2731
  • [42] Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
    Huizinga, Tom W. J.
    Torii, Yoshifumi
    Muniz, Rafael
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 41 - 61
  • [43] Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
    Tom W. J. Huizinga
    Yoshifumi Torii
    Rafael Muniz
    Rheumatology and Therapy, 2021, 8 : 41 - 61
  • [44] Clinical outcomes of switching to adalimumab biosimilar (MSB11022) in patients with rheumatoid arthritis: RESTART Spanish Registry
    Garcia-Miguel, Javier
    Yankova Komsalova, Liliya
    Mata Arnaiz, Cristina
    Alegre-Sancho, Juan Jose
    Polo, Javier Gonzalez
    Torrente-Segarra, Vicenc
    Tornero Molina, Jesus
    Angeles, Vanessa Andrea Navarro
    Carames, Cristina
    Cristobal, Ion
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (08) : 1431 - 1438
  • [45] Injection-site reactions in adalimumab rheumatoid arthritis (RA) pivotal clinical trials
    Wells, AF
    Kupper, H
    Fischkoff, S
    Chartash, E
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 411 - 411
  • [46] Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
    Weinblatt, Michael E.
    Baranauskaite, Asta
    Niebrzydowski, Jaroslaw
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Cheong, Soo Yeon
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (01) : 40 - 48
  • [47] Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
    Popescu, Claudiu Costinel
    Mogosan, Corina Delia
    Enache, Luminita
    Codreanu, Catalin
    MEDICINA-LITHUANIA, 2022, 58 (12):
  • [48] Sarcoidosis Induced by Adalimumab in Rheumatoid Arthritis
    Lee, Seung Ho
    Kim, Sa-Il
    Song, June Seok
    Kim, Tae Hyung
    Sohn, Jang Won
    Kim, Sang-Heon
    Yoon, Ho Joo
    Kim, Tae-Hwan
    Shin, Dong Ho
    Park, Sung Soo
    Kwak, Hyun Jung
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2011, 71 (06) : 464 - 469
  • [49] Adalimumab is safe in global clinical trials in multiple indications and reduced mortality in rheumatoid arthritis
    Burmester, G.
    Mease, P. J.
    Dijkmans, B. A. C.
    Gordon, K. B.
    Lovell, D. J.
    Kent, J. D.
    Pangan, A. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 181 - 182
  • [50] Long-term safety of adalimumab (humira®) in worldwide rheumatoid arthritis clinical trials
    Schiff, MH
    Burmester, GR
    Pangan, A
    Kupper, H
    Spencer-Green, GT
    RHEUMATOLOGY, 2005, 44 : I70 - I71
12345